CL2017002614A1 - Método para la purificación de proteínas - Google Patents

Método para la purificación de proteínas

Info

Publication number
CL2017002614A1
CL2017002614A1 CL2017002614A CL2017002614A CL2017002614A1 CL 2017002614 A1 CL2017002614 A1 CL 2017002614A1 CL 2017002614 A CL2017002614 A CL 2017002614A CL 2017002614 A CL2017002614 A CL 2017002614A CL 2017002614 A1 CL2017002614 A1 CL 2017002614A1
Authority
CL
Chile
Prior art keywords
protein purification
domain
provides
present
antibody
Prior art date
Application number
CL2017002614A
Other languages
English (en)
Inventor
Sam Philip Heywood
Gavin Barry Wild
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2017002614A1 publication Critical patent/CL2017002614A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>La presente invención proporciona un método para recuperar un anticuerpo humano que contiene un dominio VH3 en forma de monómeros. En particular, la presente invención proporciona un nuevo método que permite la recuperación de anticuerpos humanos que contienen el dominio V1-13 en forma de menómeros de una mezcla que contiene formas monoméricas y multiméricas del anticuerpo</p>
CL2017002614A 2015-04-22 2017-10-16 Método para la purificación de proteínas CL2017002614A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1506868.7A GB201506868D0 (en) 2015-04-22 2015-04-22 Method for protein purification

Publications (1)

Publication Number Publication Date
CL2017002614A1 true CL2017002614A1 (es) 2018-04-27

Family

ID=53299017

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002614A CL2017002614A1 (es) 2015-04-22 2017-10-16 Método para la purificación de proteínas

Country Status (19)

Country Link
US (2) US10927164B2 (es)
EP (1) EP3286205A1 (es)
JP (2) JP6866300B2 (es)
KR (1) KR102675400B1 (es)
CN (1) CN107636012B (es)
AR (1) AR104358A1 (es)
AU (1) AU2016251223B2 (es)
BR (1) BR112017022073A2 (es)
CA (1) CA2983057C (es)
CL (1) CL2017002614A1 (es)
CO (1) CO2017010631A2 (es)
EA (1) EA201792328A1 (es)
GB (1) GB201506868D0 (es)
IL (1) IL254883B (es)
MA (1) MA41941A (es)
MX (1) MX392543B (es)
MY (1) MY189854A (es)
SG (1) SG11201708256YA (es)
WO (1) WO2016169992A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013081540A1 (en) * 2011-11-30 2013-06-06 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
CN108085358A (zh) * 2018-02-08 2018-05-29 保定冀中药业有限公司 一种犬细小病毒单克隆抗体IgG2b-Fab片段的制备方法
SG11202112846RA (en) 2019-08-02 2021-12-30 UCB Biopharma SRL Methods for purifying antibodies
GB201919058D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
EP4141025A4 (en) * 2019-12-26 2024-04-24 ABL Bio, Inc. Method for purifying biologically active peptide by using protein a affinity chromatography
GB202109246D0 (en) * 2021-06-28 2021-08-11 Cytiva Bioprocess R & D Ab A method of separating bispecific antibodies
WO2025248017A1 (en) * 2024-05-31 2025-12-04 UCB Biopharma SRL Method of purifying recombinant proteins

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
WO2000069457A1 (en) 1999-05-15 2000-11-23 University Of California, San Diego Protein a based binding domains with desirable activities
EP1353937A4 (en) * 2000-12-29 2005-04-13 Savient Pharmaceuticals Inc SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY
US20060257972A1 (en) * 2003-03-31 2006-11-16 Takashi Ishihara Purification of human monoclonal antibody and human polyclonal antibody
JP5529869B2 (ja) * 2008-08-14 2014-06-25 メルク・シャープ・アンド・ドーム・コーポレーション プロテインａアフィニティークロマトグラフィーを用いる抗体の精製方法
AU2010216152B2 (en) 2009-02-17 2015-05-14 Ucb Biopharma Sprl Antibody molecules having specificity for human OX40
EA201300524A1 (ru) * 2010-11-01 2013-08-30 ДСМ АйПи АССЕТС Б.В. Очистка антител ионообменной хроматографией в едином блоке
US8859726B2 (en) 2010-11-29 2014-10-14 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
UA112203C2 (uk) * 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
JP6411214B2 (ja) 2011-11-11 2018-10-24 ユーシービー バイオファルマ エスピーアールエル アルブミン結合抗体及びその結合断片
MX2014009565A (es) * 2012-02-10 2014-11-10 Genentech Inc Anticuerpos monocatenarios y otros heteromultimeros.
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
AP2016009222A0 (en) * 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method

Also Published As

Publication number Publication date
US20210171609A1 (en) 2021-06-10
AU2016251223B2 (en) 2021-12-09
IL254883B (en) 2021-09-30
KR20170139131A (ko) 2017-12-18
CO2017010631A2 (es) 2018-01-05
JP6866300B2 (ja) 2021-04-28
GB201506868D0 (en) 2015-06-03
CN107636012A (zh) 2018-01-26
WO2016169992A1 (en) 2016-10-27
JP2018520089A (ja) 2018-07-26
US10927164B2 (en) 2021-02-23
AR104358A1 (es) 2017-07-12
JP2021066734A (ja) 2021-04-30
US20180100007A1 (en) 2018-04-12
KR102675400B1 (ko) 2024-06-13
EP3286205A1 (en) 2018-02-28
CA2983057A1 (en) 2016-10-27
IL254883A0 (en) 2017-12-31
AU2016251223A1 (en) 2017-10-26
BR112017022073A2 (pt) 2018-08-14
MX2017013333A (es) 2018-02-19
CN107636012B (zh) 2022-08-02
CA2983057C (en) 2025-05-06
MY189854A (en) 2022-03-14
SG11201708256YA (en) 2017-11-29
US12516106B2 (en) 2026-01-06
MA41941A (fr) 2018-02-28
MX392543B (es) 2025-03-19
EA201792328A1 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
MX2017013333A (es) Metodo para purificacion de proteina.
EA202092435A3 (ru) Моноклональные антитела против bcma
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CL2018000502A1 (es) Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer.
CR20170026A (es) Anticuerpos anti-tau humanizados
PL3505535T3 (pl) Przeciwciało monoklonalne anty-pd1, jego kompozycja farmaceutyczna i jego zastosowanie
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
PH12016500940A1 (en) HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
EA201691991A1 (ru) Мультиспецифические антитела
SI3176181T1 (sl) Monoklonsko protitelo proti CTLA4 ali njegov antigen-vezavni fragment, zdravilni sestavek in uporaba
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
CO2020002060A2 (es) Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
MX2015017487A (es) Anticuerpos cd3 humanizados o quimericos.
SI3561057T1 (sl) Antitelo proti cd3 in molekula, ki vsebuje navedeno antitelo
CL2017000912A1 (es) Anticuerpos que se unen a ccr6 y sus usos
CU24556B1 (es) Anticuerpos anti-basigin humanizados
EA201691702A1 (ru) Химерные белки мти
MX378855B (es) Cuantificacion de tnfr2 : fc plegada erroneamente.
EA201792492A1 (ru) Aml-антигены и их применение
AR110569A1 (es) ANTICUERPOS MONOCLONALES ANTI-a-SINUCLEÍNA PARA PREVENIR LA AGREGACIÓN DE TAU
TH1601003449A (th) Pd-1 แอนติบอดี ชิ้นส่วนที่จับกับแอนติเจนของแอนติบอดีนั้น และการใช้แอนติบอดีนั้นทางการแพทย์